ABIOMED, Inc. (NASDAQ:ABMD) Receives Average Rating of “Hold” from Analysts

ABIOMED, Inc. (NASDAQ:ABMD) has earned a consensus rating of “Hold” from the thirteen research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $186.40.

A number of equities analysts have issued reports on ABMD shares. Zacks Investment Research cut shares of ABIOMED from a “hold” rating to a “sell” rating and set a $160.00 target price on the stock. in a report on Wednesday, April 8th. OTR Global raised ABIOMED to a “positive” rating in a report on Monday, July 13th. BTIG Research lowered ABIOMED to a “hold” rating in a research report on Wednesday, May 27th. BidaskClub raised ABIOMED from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 6th. Finally, Morgan Stanley raised their target price on ABIOMED from $149.00 to $152.00 and gave the company an “underweight” rating in a research note on Friday, May 1st.

Shares of ABMD opened at $299.94 on Tuesday. The stock has a market capitalization of $13.51 billion, a PE ratio of 67.86, a price-to-earnings-growth ratio of 4.79 and a beta of 0.94. The business’s fifty day moving average price is $265.61 and its 200 day moving average price is $198.10. ABIOMED has a 12-month low of $119.01 and a 12-month high of $302.97.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.96 by ($0.26). ABIOMED had a return on equity of 18.51% and a net margin of 24.14%. The business had revenue of $206.66 million during the quarter, compared to the consensus estimate of $209.58 million. During the same quarter in the previous year, the business posted $1.60 earnings per share. The company’s quarterly revenue was down .2% compared to the same quarter last year. Sell-side analysts predict that ABIOMED will post 3.21 EPS for the current year.

In related news, Director Dorothy E. Puhy sold 7,500 shares of ABIOMED stock in a transaction dated Wednesday, July 15th. The stock was sold at an average price of $275.00, for a total transaction of $2,062,500.00. Following the transaction, the director now directly owns 7,652 shares of the company’s stock, valued at $2,104,300. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 3.40% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Fifth Third Bancorp increased its stake in ABIOMED by 12.5% in the 1st quarter. Fifth Third Bancorp now owns 550 shares of the medical equipment provider’s stock valued at $80,000 after buying an additional 61 shares during the period. CIBC Asset Management Inc grew its stake in shares of ABIOMED by 1.7% in the 2nd quarter. CIBC Asset Management Inc now owns 3,871 shares of the medical equipment provider’s stock valued at $935,000 after buying an additional 64 shares in the last quarter. Weiss Multi Strategy Advisers LLC increased its holdings in ABIOMED by 0.8% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 9,070 shares of the medical equipment provider’s stock worth $1,317,000 after buying an additional 70 shares during the last quarter. CSat Investment Advisory L.P. raised its position in ABIOMED by 17.1% during the first quarter. CSat Investment Advisory L.P. now owns 494 shares of the medical equipment provider’s stock valued at $72,000 after acquiring an additional 72 shares in the last quarter. Finally, Comerica Bank raised its position in ABIOMED by 0.8% during the second quarter. Comerica Bank now owns 8,906 shares of the medical equipment provider’s stock valued at $2,647,000 after acquiring an additional 74 shares in the last quarter. Institutional investors own 94.43% of the company’s stock.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Article: Cash Flow Analysis in Stock Selection

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.